Bayer HealthCare, a Germany Headquarter Chemical Company, is buying Teva Pharmaceuticals, a US-based animal health business, for USD 60 million up front, plus up to USD 85 million in manufacturing and sales milestones. Bayer HealthCare maintains taking on Teva’s the animal health operation will allow the expansion of its companion (pet food) and food animal product lines in the U.S., including the introduction of anti-infective and reproductive hormones. The Teva business will be integrated into Bayer’s own animal health business.
Featured News
Tech Policy and Regulation Weekly Roundup
Jan 23, 2026 by
CPI
Perkins Coie Adds Former DOJ Antitrust Leader as Partner in Washington
Jan 22, 2026 by
CPI
Ryanair Boss Dismisses Musk’s Buyout as Starlink Feud Escalates
Jan 22, 2026 by
CPI
Paramount Extends Warner Bros Bid as Netflix Rivalry Heats Up
Jan 22, 2026 by
CPI
South Korea Breaks New Ground With Landmark AI Law
Jan 22, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Recidivism
Jan 21, 2026 by
CPI
Recidivism, Multiple Offending, and Serial Offending in Antitrust
Jan 21, 2026 by
Gregory Werden
Antitrust Recidivism: Why Repeat Cases Appear, and Why True Reoffending Is Rare in the United States
Jan 21, 2026 by
Lisa M. Phelan, Megan S. Golden, Adrienne Irmer & Nina Worth
99 Antitrust Problems – Is Recidivism One?
Jan 21, 2026 by
Brian A. Ratner & Kartik S. Madiraju
Holding A Cat by the Tail: A View of Cartel Recidivism in U.S. Antitrust Enforcement
Jan 21, 2026 by
Mark Rosman & KaDee L. Ru